Neuropad is a new indicator test used to diagnose @entity409 , a component of @entity4148 . In this cross-sectional study, Neuropad is evaluated and compared with corrected QT (QT c), another test used in the diagnosis of @entity4148 . The indicator test measures sweat production on the basis of a color change of @entity5303 solution from blue to pink upon absorption of water. This study involved 105 @entity1 (43 @entity1 , 62 @entity1 ) with type 2 @entity6 with a mean age of 56.2+/-11.5 y and a mean disease duration of 10.0+/-6.3 y. Age, sex, disease duration, glycosylated hemoglobin, and QT c were compared between @entity1 with normal and abnormal test results. The QT c interval was measured and the new indicator test was applied in all @entity1 . The 2 tests were compared, and the sensitivity, specificity, positive predictive value, and negative predictive value for the indicator test were calculated. @entity4148 was diagnosed in 40 @entity1 (38.1%) with QT c interval measurement and in 72 @entity1 (68.6%) with the new indicator test (P=.001). The sensitivity, specificity, positive predictive value, and negative predictive value for the indicator test were 87.5%, 43.1%, 48.6%, and 84.8%, respectively. @entity1 with abnormal test outcomes had longer QT c than those whose test results were normal (0.433 vs 0.398 s; P=.002). Study results suggest that the new indicator test has an acceptable sensitivity but a low specificity and is not superior to other tests in the diagnosis of @entity409 .

Neuropad indicator test for diagnosis of XXXX in type 2 @entity6 .

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity5303 :: ('MESH:C018021', 'Chemical') :: ['cobalt (II) chloride'] @entity409 :: ('MESH:D008107', 'Disease') :: ['sudomotor dysfunction'] @entity4148 :: ('MESH:D001342', 'Disease') :: ['Autonomic neuropathy', 'autonomic neuropathy']
@entity409 :: (MESH:D008107,Disease) :: ['sudomotor dysfunction']
